MedTrace Logo

Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma

NCT00003337 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-08-16

No results posted yet for this study

Summary

RATIONALE: Diagnostic imaging procedures using radiolabeled monoclonal antibodies may improve the ability to detect and stage non-Hodgkin's lymphoma.

PURPOSE: Phase III trial to study the effectiveness of a radiolabeled monoclonal antibody in the detection and staging of patients with non-Hodgkin's lymphoma.

Conditions

Interventions

PROCEDURE

immunoscintigraphy

RADIATION

technetium Tc 99m epratuzumab

Sponsors & Collaborators

Principal Investigators

  • William A. Wegener, MD, PhD · Gilead Sciences

Study Design

Purpose
DIAGNOSTIC

Eligibility

Min Age
16 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-03-31

Countries

  • United States
  • Austria
  • Italy
  • Sweden
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003337 on ClinicalTrials.gov